Skip to main content

Table 1 Clinical characteristics of all obese with NAFLD children

From: Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease

Variable

rhGH group

(n = 22)

control group

(n = 22)

p value

Age (yr)

12.04 ± 1.56

11.48 ± 1.78

0.272

Prepuberty/Puberty, (n)

16/6

15/7

0.741â–²

BMI SDS

2.56 ± 0.65

2.75 ± 0.61

0.321

CRP(mg/L)

1.75 ± 1.06

2.06 ± 1.22

0.378

ALT(U/L)

24.50(14.75, 46.00)

26.53(17.00, 60.25)

0.452â–²

AST(U/L)

25.50(22.00, 29.75)

24.50(21.50, 34.25)

0.953â–²

GGT(U/L)

21.50(17.00, 30.00)

28.00(21.00, 31.75)

0.09â–²

TC(mmol/L)

4.57 ± 0.60

4.46 ± 0.97

0.654

HDL-C (mmol/L)

1.24(1.07, 1.40)

1.20(1.07, 1.37)

0.717#

LDL-C (mmol/L)

2.71 ± 0.45

2.68 ± 0.79

0.870

TG(mmol/L)

1.32(0.84, 1.87)

1.21(0.92, 1.58)

0.988#

UA(μmol/L)

381.05 ± 112.52

370.90 ± 68.55

0.720

Insulin(uIU/mL)

24.13 ± 11.41

25.91 ± 13.01

0.631

FBG(mmol/L)

5.17 ± 0.39

5.18 ± 0.38

0.972

HOMA-IR

5.58 ± 2.79

5.99 ± 3.13

0.648

WBISI

3.22 ± 1.16

2.84 ± 1.52

0.349

HbA1c (%)

5.68 ± 0.24

5.66 ± 0.34

0.839

  1. # p value reported for log transformed values, but values in the table represent as the median (interquartile range) ▲Mann–Whitney U test or chi square test
  2. * p < 0.05
  3. Abbreviations: BMI SDS body mass index standard deviation scores, CRP C reactive protein, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, TC Total cholesterol, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, TG Triglycerides, UA Uric acid, FBG Fasting blood glucose, HOMA-IR Homeostasis model assessment of IR, WBISI Whole body insulin sensitivity index, HbA1c Glycosylated haemoglobin